Provision Language
Novartis – MPP Agreement
12. Term and termination
12.1. The term of this Agreement shall commence on the Effective Date and, unless terminated earlier in accordance with its terms, this Agreement shall continue in force, on a country-by-country basis, until the expiration, lapse or invalidation of the last remaining (i) Manufacturing Patent (expiry 4 July 2023) for use, offer for sale, sale, export or import of the Product in the Territory or (ii) or any Patent. Clause 2.1(a) of this Agreement which grants MPP a non-exclusive license under the Manufacturing Patent shall expire upon expiry, lapse, or invalidation of the Manufacturing Patent (expiry 4 July 2023), and clause 2.1(a) of this Agreement which grants MPP a non-exclusive license under the Patents and clause 2.1(b) of this Agreement shall continue in force on a country-by-country basis pursuant to Clause 12.1 after such expiry, lapse or invalidation of the Manufacturing Patent as applicable.
Form of Sublicense
13 TERM AND TERMINATION
13.1 This Agreement shall be deemed to come into effect on the Sublicence Effective Date and shall continue thereafter subject to the further provisions of this Clause 13.
13.2 Unless otherwise terminated, this Agreement shall expire, on a country-by-country basis, upon the expiration, lapse or invalidation of the last remaining (i) Manufacturing Patent (expiry 4 July 2023) for use, offer for sale, sale, or import of the Product in the Territory or (ii) any Patent. Clause 2.1(a) of this Agreement which grants the Licensee a nonexclusive license under the Manufacturing Patent shall expire upon expiry, lapse, or invalidation of the Manufacturing Patent (expiry 4 July 2023), clause 2.1(a) of this Agreement which grants MPP a non-exclusive license under the Patents and and clause 2.1(b) of this Agreement shall continue in force on a country-by-country basis pursuant to Clause 13.2 after such expiry, lapse or invalidation of the Manufacturing Patent as applicable.